Tetrahydroquinazoline derivatives as selective cytotoxic agents

US11648250B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Antonella Converso · Cheltenham, US
• Abdellatif El Marrouni · Ambler, US
• Anthony W. Shaw · Johnstown, US
• David N. Hunter · Hatfield, US
• Ashley Forster · Gilbertsville, US
• Cheng Wang · Fort Washington, US
• Yunlong Zhang · North Haven, US

Key dates

• Filing date: Aug 25, 2021
• Grant date: May 16, 2023
• Expiry date: Sep 17, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D403/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure is directed to tetrahydroquinazoline derivatives of Formula I and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV naïve cells, and for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).